|
Market Closed -
Nasdaq Copenhagen
08:50:00 04/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 43.85 DKK | -0.23% |
|
+6.82% | +21.13% |
| 03/09 | H. Lundbeck A/S Highlights Mechanistic Insights and Clinical Data on Bexicaserin At the European Epilepsy Congress | CI |
| 03/09 | Lundbeck presents new data on bexicaserin | FW |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- HLUN B Stock
- LUN Stock
- Consensus Lundbeck
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
